Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/1/2025

Resumption of Xeplion Depot Therapy

Patient Management

  • The patient, who had been receiving Xeplion Depot 150mg as a maintenance dose for years, can continue with the same dose after a 7-week interruption of depot therapy and temporary oral substitution with Paliperidon, without requiring re-initiation of the initial dose 1
  • Close monitoring for psychotic symptoms is recommended in the first 2-4 weeks after resuming depot therapy, especially in patients who have undergone a 7-week interruption of Xeplion Depot therapy 2
  • The maintenance dose of 150mg should be continued, provided there are no adverse reactions, and the patient's condition remains stable, as per the guidelines from a reputable medical society 1
  • Documentation of target symptoms, treatment response, and potential side effects is essential for patients receiving Xeplion Depot therapy, as recommended by a guideline society 1
  • Monitoring for known side effects such as extrapyramidal symptoms, weight gain, and metabolic changes is crucial for patients on Xeplion Depot therapy, according to a medical guideline society 1
  • If the patient has a history of good tolerance and stable condition, the maintenance dose of 150mg can be continued, as suggested by a reputable medical guideline society 2, 1

REFERENCES